The most common were categorized as device-related (6), cardiac (4), gastrointestinal (4), and bleeding/hematoma (3). The perioperative 30-day mortality rate was 3.1% (10 of 322). Mean follow-up was 25.7 months (range, 1-110 months). Overall, 47 patients (14.6%) required secondary intervention, 7 patients (2.2%) underwent conversion

to open repair, and selleck products 4 patients (1.2%) died from AAA rupture. Endoleaks occurred in 95 patients (29.4%), with 20 type 1, 48 type II, and 27 of indeterminate type; of these, 10 patients with type I endoleaks underwent secondary intervention. Freedom from all-cause mortality at 1 year was 84.3% and at 5 years was 27.4%. Freedom from aneurysm-related mortality at 5 years was 92.9%.

Conclusion: EVAR in octogenarians is associated with high procedural success and low perioperative morbidity and mortality. The midterm results of this study support

the use of EVAR in this patient population. Further studies are eeded to predict short-term and long-term mortality risk, and treatment for other causes of death. (J Vase Surg 2010; 51:1354-9.)”
“Introduction: Aneurysmal involvement of the iliac bifurcation increases the level of difficulty during surgery for abdominal aortic aneurysm (AAA) repair, potentially increasing the risk of early postoperative complications. Three previous randomized trials comparing endovascular aneurysm repair (EVAR) and open repair (OR) for AAAs showed that EVAR is associated with a lower early mortality rate. However, whether learn more these results are valid for AAA involving the iliac bifurcation (AAAIB) remains unclear. The aim of this study was to evaluate early and late results after OR and EVAR for patients with AAA involving the iliac bifurcation.

Methods: Of 1116 patients treated for elective AAA repair between January 1998 and January 2008, 131 presented with AAAIB as detected by computed tomography (CT) scan. Sixty-eight patients were treated by EVAR and 63 by OR. Clinical and anatomic data, operative intervention, and outcomes were

collected prospectively and analyzed retrospectively. The median duration of follow-up was 38 months for both groups.

Results: Patients in the EVAR group (72 +/- 10 years) were older Clomifene than those in the OR group (64 +/- 8 years; P < .0001), but there were no differences in cardiac, renal, or pulmonary comorbidities between the two groups. Inhospital mortality rates were 2.9% vs 6.3% for EVAR and OR groups, respectively (P = .43). Systemic postoperative complications occurred in 7.4% vs 9.5% (P = .76) and postoperative colonic ischemia in 0% vs 6.3% (P = .051) of patients with EVAR and OR, respectively. Survival rates by Kaplan-Meier analysis were 91 +/- 7% for patients with EVAR and 90 +/- 8% for patients with OR at 2 years, and 61% 15 for EVAR and 79% +/- 13 for OR at 5 years. All-cause rcoperation rates were 25% with EVAR and 22% with OR ( P = .83). Patients with EVAR were more likely to develop buttock claudication (33.3% vs 3.